Skip to main content

Table 2 Proportion of trough FEV1 SAC-TDI, E-RS responders and GADS assessment

From: Salbutamol use in relation to maintenance bronchodilator efficacy in COPD: a prospective subgroup analysis of the EMAX trial

 

High baseline SABA (≥1.5 puffs/day)

Low baseline SABA (< 1.5 puffs/day)

UMEC/VI

UMEC

SAL

UMEC/VI

UMEC

SAL

Trough FEV1 respondersa, n/N (%)

193/411 (47)

131/391 (34)

90/387 (23)

173/383 (45)

114/384 (30)

80/398 (20)

 UMEC/VI vs comparator odds ratio (95% CI)

1.81 (1.35, 2.42); p < 0.001

3.07 (2.25, 4.21); p < 0.001

2.03 (1.49, 2.76); p < 0.001

3.44 (2.48, 4.77); p < 0.001

SAC-TDI respondersb, n/N (%)

220/415 (53)

170/398 (43)

164/394 (42)

183/389 (47)

162/398 (41)

166/412 (40)

 UMEC/VI vs comparator odds ratio (95% CI)

1.52 (1.14, 2.02); p = 0.004

1.60 (1.20, 2.13); p = 0.001

1.34 (1.01, 1.79); p = 0.044

1.37 (1.03, 1.82); p = 0.031

E-RS respondersc, n/N (%)

163/415 (39)

124/401 (31)

122/396 (31)

127/394 (32)

95/399 (24)

95/412 (23)

 UMEC/VI vs comparator odds ratio (95% CI)

1.47 (1.10, 1.98); p = 0.010

1.47 (1.10, 1.98); p = 0.011

1.57 (1.14, 2.17); p = 0.006

1.59 (1.16, 2.19); p = 0.004

GADSd, n/N (%)

246/363 (68)

187/305 (61)

202/322 (63)

227/342 (66)

205/332 (62)

211/352 (60)

 UMEC/VI vs comparator odds ratio (95% CI)

1.38 (1.05, 1.82); p = 0.020

1.26 (0.96, 1.65); p = 0.097

1.41 (1.08, 1.86); p = 0.013

1.55 (1.18, 2.04); p = 0.002

  1. aTrough FEV1 responders were defined as patients with ≥100 mL trough FEV1 improvement from baseline at Week 24; bSAC-TDI responders were defined as patients with a score ≥ 1 at Week 24; cE-RS responders were defined as patients with ≥2-point improvement from baseline at Weeks 21─24; dpatients with a GADS response category of ‘slightly better’, ‘better’ or ‘much better’ at Week 24
  2. CI confidence interval, E-RS Evaluating Respiratory Symptoms: COPD, FEV1 forced expiratory volume in 1 s, GADS global assessment of disease severity, SABA short-acting β2-agonist, SAC-TDI self-administered computerised Transition Dyspnoea Index, SAL salmeterol, UMEC umeclidinium, VI vilanterol